Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will release fourth quarter and full year 2023 results after the market closes on Monday, March 18, 2024. Following the release, management will host a conference call and audio webcast to review results and provide a brief business and outlook update that same day at 1:30 p.m. PT / 4:30 p.m. ET.
- Live conference call: 877-407-3982 (Toll-Free) and 201-493-6780 (International)
- Live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1656407&tp_key=3507378dc0
An archived replay will be available following the call on Augmedix's IR website at https://ir.augmedix.com/.
About Augmedix
Augmedix (NASDAQ:AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners.
Augmedix is on a mission to help clinicians and patients form a human connection by seamlessly integrating our technology at the point of care. Augmedix's proprietary platform digitizes natural clinician-patient conversations, which are converted into comprehensive medical notes and structured data in real time. The company's platform uses automatic speech recognition, and natural language processing, including large language models, to generate accurate and timely medical notes that are transferred into the EHR.
Augmedix's products relieve clinicians of administrative burden, in turn, reducing burnout, increasing clinician efficiency and improving patient access. Through Augmedix's proprietary platform and bi-directional communication channel, Augmedix is ideally suited to serve as the vehicle for change at the point of care.
Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.
Contact Information
Investors:
Matt Chesler, CFA
FNK IR
(646) 809-2183
[email protected]
[email protected]
Media:
Kaila Grafeman
Augmedix
[email protected]
